Cargando…

Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is an uncommon but aggressive subtype of breast cancer. Obesity has been associated with an increased risk of breast cancer and worse prognosis. Some studies suggest that obese patients are less likely to achieve pathologic complete response (pCR) to neoadjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, Jean, Borja, Nicholas, Rao, Madhu, Huth, James, Leitch, A Marilyn, Rivers, Aeisha, Wooldridge, Rachel, Rao, Roshni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402063/ https://www.ncbi.nlm.nih.gov/pubmed/25641925 http://dx.doi.org/10.1002/cam4.388

Ejemplares similares

Mammographic density changes in surgical weight loss-an indication for personalized screening
por: Partain, Natalia, et al.
Publicado: (2018)

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Vernaci, Grazia, et al.
Publicado: (2023)

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
por: Talamantes, Sarah, et al.
Publicado: (2020)

Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy
por: Zhao, Yanding, et al.
Publicado: (2020)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
por: Prakash, Ipshita, et al.
Publicado: (2022)

Pathological features of triple‐negative breast cancers that showed progressive disease during neoadjuvant chemotherapy
por: Tanabe, Yuko, et al.
Publicado: (2017)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer
por: Chen, Victor E., et al.
Publicado: (2017)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response
por: Mohammed, Amrallah A, et al.
Publicado: (2020)

Pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy
por: Eguchi, Yuki, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy
por: Masuda, Hiroko, et al.
Publicado: (2022)

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
por: Ruan, Miao, et al.
Publicado: (2018)

Study of diffusion‐weighted magnetic resonance imaging in the evaluation of the response to AAV2‐VEGF‐Trap neoadjuvant treatment in a triple‐negative breast cancer animal model
por: Li, Jianhua, et al.
Publicado: (2019)

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
por: Wu, Kunpeng, et al.
Publicado: (2014)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
por: Abd El-Aziz, Yomna S., et al.
Publicado: (2021)

A Bayesian network meta‐analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple‐negative breast cancer
por: Chen, Huihui, et al.
Publicado: (2018)

Strong impact of pathological node-negative on long-term overall survival of patients with triple-negative breast cancer receiving neoadjuvant chemotherapy
por: Nogi, Hiroko, et al.
Publicado: (2021)

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy
por: Pataer, Apar, et al.
Publicado: (2018)

Direct comparison of magnetic resonance imaging and pathological shrinkage patterns of triple-negative breast cancer after neoadjuvant chemotherapy
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2020)

A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes
por: Huang, Liang, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
por: Weng, Zeng-Jie, et al.
Publicado: (2021)

Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers
por: Srivastava, Pooja, et al.
Publicado: (2022)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

CT Radiomics for Predicting Pathological Complete Response of Axillary Lymph Nodes in Breast Cancer After Neoadjuvant Chemotherapy: A Prospective Study
por: Li, Yan-Ling, et al.
Publicado: (2023)

Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
por: Arbore, Giuseppina, et al.
Publicado: (2023)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Yoon Yang, et al.
Publicado: (2016)

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
por: Zhang, Wei, et al.
Publicado: (2023)

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
por: Zapperi, Stefano, et al.
Publicado: (2023)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
por: Litton, Jennifer K, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_phmb0i6bjtr6h7tip7s0sapbml